Dapoflit TM 500 Tablet is a scientifically balanced triple-drug formulation combining Dapagliflozin 10mg, Teneligliptin 20mg, and Metformin 500mg, designed for comprehensive management of type-2 diabetes mellitus. This synergistic combination targets multiple pathways to improve glycemic control, reduce insulin resistance, and maintain stable blood glucose levels throughout the day.
Dapagliflozin promotes glucose excretion via the kidneys, Teneligliptin enhances incretin-mediated insulin secretion, and Metformin improves insulin sensitivity while reducing hepatic glucose production. Together, these agents provide effective fasting and post-prandial glucose control with improved metabolic outcomes.
From a business perspective, Dapoflit TM 500 Tablet is a high-rotation anti-diabetic product, widely prescribed by physicians, diabetologists, and endocrinologists. Rising diabetes prevalence ensures continuous demand across OPD clinics, hospital pharmacies, chronic-care centers, and retail pharmacies.
Adding Dapoflit TM 500 to your portfolio strengthens your diabetes and metabolic-care segment, opening opportunities in institutional supply, pharmacy networks, hospital procurement, export markets, and third-party manufacturing. Its triple-mechanism action and strong prescription acceptance make it a commercially valuable and clinically essential product.